Current Cancer Trials
Participate in One of These Clinical Trials
National Cancer Institute Trials:
With a grant from the National Cancer Institute (NCI), more than 30 established, recognized clinical oncology programs have joined together to form the Northwest Community Oncology Research Program (NW NCORP).
MultiCare Health System is amongst a network of hospitals, clinics, physicians, and researchers working together to provide cancer education and access to new and unique cancer clinical trials to the men, women, and children in communities across Washington, Utah and Alaska.
Visit NW NCORP website for NCI Clinical Trials available at MultiCare
Cancer Clinical Trials offered by MultiCare Health System
Brain
Breast - Triple Negative
B-59/GBC 96
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
NRG BR003
A randomized Phase III trial of adjuvant therapy comparing Doxorubicin plus Cyclophosphamide followed by weekly Paclitaxel with or without Carboplatin for node-positive or high-risk node-negative triple-negative invasive breast cancer
EA1131
A randomized Phase III post-operative trial of platinum-based chemotherapy vs. observation in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy
S1418/BR006
A randomized Phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with ≥1 cm residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy
Breast - Node Positive
A011202
A randomized Phase III trial comparing Axillary Lymph Node Dissection to Axillary Radiation in breast cancer patients (cT1-3 N1) who have positive Sentinel Lymph Node Disease after neoadjuvant chemotherapy
NSABP B51
Randomized Phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy
A011502
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Breast - ER/PR Positive HER2-Negative
SWOG 1207
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of Everolimus in patients with high-risk, hormone receptor-positive and HER2-neg breast cancer
Breast - HER2 Positive Metastatic
DS8201-A-U301
A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1
DS8201-A-U302
A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
S1501
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER‐2+ Breast Cancer, Phase III
Breast - Other
A011401
(BWEL) Randomized Phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer
NRG‐CC004
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
Pancreas
8951-CL-5201
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Sequoia AM0010-301
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Gastrointestinal - Colon
S0820
A Double Blind Placebo‐Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0‐III Colon or Rectal Cancer, Phase III‐ Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Gastrointestinal - Metastatic Pancreas
8951-CL-5201
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Sequoia AM0010‐301
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second‐line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First‐Line Gemcitabine Containing Regimen
Gastrointestinal - Rectal
NRG-GI002
Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Genitourinary - Prostate
TRITON3 CO-338-063
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
NRG‐GU002
A Phase II‐III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Genitourinary - Bladder
A031501
A Phase 3 Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
S1602
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG‐Naive High‐Grade Non‐Muscle Invasive Bladder Cancer
Gynecologic - Ovarian
NRG‐GY009
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP‐Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP‐Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
Gynecologic - Uterine or Vaginal
NRG‐GY006
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II‐IVA Vaginal Cancer
Gynecologic - Other
NRG‐CC004
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
Head and Neck
NRG HN004
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
AG013-ODOM-201A (ORAGENICS)
A Phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy
Lung
LUNGMAP
A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
HS-10296-12-01 (Hansoh)
A Phase 1/2, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of oral once-daily administration of HS-10296 in patients with locally advanced or metastatic non-small cell lung cancer who have progressed following prior therapy with an epidermal growth factor receptor Tyrosine Kinase inhibitor agent
A081105-EGFR
Randomized, double-blind, placebo-controlled study of Erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer.
A211401
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke
Cigarettes
A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Melanoma
EA6134
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
S1616
A Phase II Randomized Study of Nivolumab (NSC‐748726) with Ipilimumab (NSC‐732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti‐PD1 or Anti‐PD‐L1 Agent
Other (Tumor Profiling, Registries, etc.)
STR-001-001
An Observational Study profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations
DCP-001
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
S1415CD
A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia — Trial Assessing CSF Prescribing Effectiveness and Risk (Tracer).
S1609
DART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors
EAY131
Molecular Analysis for Therapy Choice (MATCH)
PCYC-1134M
A disease registry for patients with Chronic Lymphocytic Leukemia.
PRECISION MED 6504
Collection of blood, urine, and tissue samples from patients with malignant tumors
AFT-28
Direct Oral Anticoagulants (DOACS) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS TRIAL). Arm 1
Pediatric/Adolescent and Young Adult Trials
AALL1131
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
AAML1331
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
ACNS0831
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
ACNS1422
Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
AEWS1221
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
ANHL12P1
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
AHOD1331
Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
AGCT1531
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
ARST1431
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
